Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMO | Q99835 | 5/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.44 |
| ▸ | PTGES | O14684 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10065009 | 0.94 | MAPT (0.47) | MAPTTP53NPC1RAB9ASMO | |
| SCHEMBL2613324 | 0.89 | MAPT (0.50) | MAPTTP53NPC1RAB9ASMO | |
| SCHEMBL10065837 | 0.86 | TP53 (0.49) | MAPTTP53NPC1RAB9ASMO | |
| SCHEMBL2612605 | 0.86 | ALDH1A1 (0.49) | MAPTTP53NPC1RAB9ASMO | |
| SCHEMBL2612653 | 0.86 | LMNA (0.51) | MAPTTP53NPC1RAB9ASMO | |
| SCHEMBL2612642 | 0.84 | ALDH1A1 (0.57) | MAPTTP53NPC1RAB9ASMO | |
| SCHEMBL2612603 | 0.84 | TP53 (0.50) | MAPTTP53NPC1RAB9ASMO | |
| SCHEMBL12284788 | 0.83 | PTGES (0.57) | MAPTTP53NPC1RAB9ASMO | |
| SCHEMBL2613294 | 0.83 | TP53 (0.48) | MAPTTP53NPC1RAB9ASMO | |
| SCHEMBL2612615 | 0.82 | TP53 (0.48) | MAPTTP53NPC1RAB9ASMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871948-B2 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| US-8871948-B2 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| US-20130158269-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | AZIENDE CHIMICHE RIUNITE ANGELIN FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-06-20 | — | — | US | disclosed |
| US-20130158269-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | AZIENDE CHIMICHE RIUNITE ANGELIN FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-06-20 | — | — | US | disclosed |
| US-8399477-B2 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESO A.C.R.A.F. S.P.A. (IT) | 2013-03-19 | — | — | US | disclosed |
| US-8399477-B2 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESO A.C.R.A.F. S.P.A. (IT) | 2013-03-19 | — | — | US | disclosed |
| US-20100286189-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | Aziende Chim. Riun.Ang.Franc. A.C.R.A.F.S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-20100286189-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | Aziende Chim. Riun.Ang.Franc. A.C.R.A.F.S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286189-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | IDO1, CYP51A1, WEE1 | MAPT 3775/4885TP53 665/4885NPC1 2591/4885 |
| US-20130158269-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | IDO1, CYP51A1, WEE1 | MAPT 3775/4885TP53 665/4885NPC1 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.